BIOS Capital Management LP Buys Shares of 1,207,709 Lantern Pharma Inc. (NASDAQ:LTRN)

BIOS Capital Management LP bought a new stake in shares of Lantern Pharma Inc. (NASDAQ:LTRN) during the 4th quarter, HoldingsChannel reports. The firm bought 1,207,709 shares of the company’s stock, valued at approximately $3,853,000. Lantern Pharma accounts for about 4.1% of BIOS Capital Management LP’s portfolio, making the stock its 4th biggest position. BIOS Capital Management LP owned 0.11% of Lantern Pharma as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new stake in Lantern Pharma during the 4th quarter valued at $32,000. Westside Investment Management Inc. boosted its stake in Lantern Pharma by 166.5% during the 3rd quarter. Westside Investment Management Inc. now owns 30,650 shares of the company’s stock valued at $112,000 after purchasing an additional 19,150 shares during the last quarter. Finally, CM Management LLC boosted its stake in Lantern Pharma by 8.1% during the 4th quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $638,000 after purchasing an additional 15,000 shares during the last quarter. 28.62% of the stock is currently owned by hedge funds and other institutional investors.

Lantern Pharma Trading Up 1.6 %

Shares of LTRN opened at $3.80 on Monday. The business’s fifty day simple moving average is $4.27 and its two-hundred day simple moving average is $3.78. Lantern Pharma Inc. has a 12 month low of $2.79 and a 12 month high of $11.99. The company has a market cap of $40.98 million, a price-to-earnings ratio of -2.13 and a beta of 1.64.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.